Netherlands-based argenx SE released a summary of its preliminary 2024 financial results on 13 January showing that global sales of its antibody drugs for autoimmune indications reached $2.2 billion last year of which $737 million was generated in the fourth quarter. In a statement, Tim Van Hauwermeiren, the chief executive, said the company is on course to be profitable in 2025. Founded in 2008, argenx has built a portfolio of antibody therapies based on discoveries around the neonatal Fc receptor which is responsible for maintaining the circulation if immunoglobuline G (IgG) in the body.
